Matthew Oberley, Chief Clinical Officer and Senior Vice President at Caris Life Sciences, shared a post on LinkedIn about a paper he co-authored with colleagues published in Clinical Cancer Research:
“Direct measurement of clonal hematopoiesis by sequencing avoids interference with interpretation of liquid biopsies in patients with solid tumors.
But at a larger level, discrimination as to the source of somatic variants in plasma by independent sequencing of the plasma and white cell compartments boosts signal-to-noise with applications like tumour-naive minimal residual disease testing and allows tumor-normal analysis from liquid biopsy for downstream therapy design.
I am very happy to see this Precision Oncology Alliance collaboration published in Clinical Cancer Research today.”
Authors: Daniel Magee, Valeriy Domenyuk, Jim Abraham, Matthew Oberley, Milan Radovich, David Spetzler et al.
More posts featuring Matthew Oberley.